Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer Zhang X; Chang AJ Med Genet 2007[Mar]; 44 (3): 166-72Frequent overexpression of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), have been developed and approved by the US Food and Drug Administration for second-line and third-line treatment of advanced NSCLC. Clinical trials have shown considerable variability in the response rate between different patients with NSCLC, which led to the discovery of somatic EGFR-activating mutations. This brief review summarises the discovery and functional consequences of the mutations, their clinicopathological features and significant implications in the treatment and prognosis of NSCLC.|*Genes, erbB-1[MESH]|*Mutation[MESH]|Adenocarcinoma/drug therapy/enzymology/genetics[MESH]|Carcinoma, Non-Small-Cell Lung/drug therapy/enzymology/*genetics[MESH]|Cell Transformation, Neoplastic/genetics[MESH]|Clinical Trials, Phase II as Topic[MESH]|DNA Mutational Analysis[MESH]|DNA, Neoplasm/genetics[MESH]|Double-Blind Method[MESH]|Drug Delivery Systems[MESH]|Drug Design[MESH]|Drug Resistance, Neoplasm[MESH]|ErbB Receptors/antagonists & inhibitors/*physiology[MESH]|Ethnicity/genetics[MESH]|Exons/genetics[MESH]|Female[MESH]|Gefitinib[MESH]|Genes, p53[MESH]|Genes, ras[MESH]|Genotype[MESH]|Humans[MESH]|Lung Neoplasms/drug therapy/enzymology/*genetics[MESH]|Male[MESH]|Mutagenesis, Insertional[MESH]|Mutation, Missense[MESH]|Protein Structure, Tertiary/genetics[MESH]|Quinazolines/pharmacology/therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Sequence Deletion[MESH]|Smoking[MESH] |
